Py-FGGK 

Py-FGGK is a gelatinase-responsive short peptide. Py-FGGK can specifically target MRSA, cause leakage of cellular components, generate ROS in situ, and kill biofilm-encapsulated MRSA cells. Py-FGGK can promote cell migration to aid wound healing, and accelerates wound healing in MRSA-infected rat models. Py-FGGK can be used in studies related to MRSA infection^[1].

The critical aggregation concentration of Py-FGGK in PBS aqueous buffer is 63.1 μM, and this concentration decreases to 39.8 μM after treatment with gelatinase, thereby promoting fibril formation^[1].
Py-FGGK (300 μM; 0-24 h) adopts a random coil conformation in aqueous PBS solution, and transforms into an α-helical structure after incubation with 0.5 μg/mL gelatinase for 6 to 24 h, which corresponds to its cleavage into Py-FG^[1].
Py-FGGK binds to HPS with moderate affinity, with a K_d value of 32.47 μM, and this binding process is mediated by its KKQK motif^[1].
Py-FGGK potently inhibits the growth of MRSA with an MIC of 1 μM, and it kills MRSA with an MBC of 10 μM^[1].
Py-FGGK (0.5-2 μM; 15 min-4 h) rapidly depolarizes the cell membrane of MRSA, induces significant leakage of cellular components from MRSA, and stimulates reactive oxygen species production in MRSA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Py-FGGK accelerates wound healing in female albino Wistar rats, achieving ~90% wound closure by day 10 and promoting enhanced tissue regeneration and collagen deposition^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1830.23

C₉₃H₁₃₆N₂₄O₁₅

{4-(pyren-4-yl)butanoic acid}-Phe-Phe-Arg-Pro-Leu-Gly-Val-Arg-Gly-Lys-Lys-Gln-Lys-NH2

{4-(pyren-4-yl)butanoic acid}-FFRPLGVRGKKQK-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bose S, et al. Gelatinase-Responsive Short Peptide Conjugate as a Precision Therapy Against Methicillin-Resistant Staphylococcus aureus. J Am Chem Soc. 2025 Oct 15;147(41):37398-37413.